© 2023 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal
Opinion: Purple Book Patent Listings Are Only a First Step
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
Contributor: Interchangeability Is a Dispensing Issue, Not a Prescribing One
Study: Denosumab Biosimilar Looks Promising for Osteoporosis in Phase 3 Trial
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?
Americans Say Drug Costs Are Too High, and They Are Right
Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development